Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Development of robust discriminant equations for assessing subtypes of glioblastoma biopsies.

Castells X, Acebes JJ, Majós C, Boluda S, Julià-Sapé M, Candiota AP, Ariño J, Barceló A, Arús C.

Br J Cancer. 2012 May 22;106(11):1816-25. doi: 10.1038/bjc.2012.174. Epub 2012 May 8.

PMID:
22568967
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1349-55. doi: 10.3174/ajnr.A2950. Epub 2012 Feb 9.

PMID:
22322613
[PubMed - indexed for MEDLINE]
Free Article
3.

IDH1 mutation of gliomas with long-term survival analysis.

Myung JK, Cho HJ, Park CK, Kim SK, Phi JH, Park SH.

Oncol Rep. 2012 Nov;28(5):1639-44. doi: 10.3892/or.2012.1994. Epub 2012 Aug 24.

PMID:
22922798
[PubMed - indexed for MEDLINE]
4.

Clinicopathologic and genomic features of gliosarcomas.

Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH.

J Neurooncol. 2012 May;107(3):643-50. doi: 10.1007/s11060-011-0790-3. Epub 2012 Jan 20.

PMID:
22270848
[PubMed - indexed for MEDLINE]
5.

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.

PMID:
22287028
[PubMed - indexed for MEDLINE]
6.

[Analyses of IDH1 mutation and MGMT promoter methylation status for 5 cases of long-term survivors with glioblastoma].

Kamoshima Y, Motegi H, Terasaka S, Kobayashi H, Yamaguchi S, Murata J, Tanaka S, Houkin K.

No Shinkei Geka. 2012 Feb;40(2):129-35. Japanese.

PMID:
22281465
[PubMed - indexed for MEDLINE]
7.

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.

PMID:
20160062
[PubMed - indexed for MEDLINE]
Free Article
8.

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.

Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E, Schulz M, Hutter G, Hench J, Schucht P, Boulay JL, Mariani L.

Neuro Oncol. 2013 Apr;15(4):469-79. doi: 10.1093/neuonc/nos317. Epub 2013 Feb 13.

PMID:
23408861
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M.

J Clin Oncol. 2009 Dec 1;27(34):5743-50. doi: 10.1200/JCO.2009.23.0805. Epub 2009 Oct 5.

PMID:
19805672
[PubMed - indexed for MEDLINE]
10.

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.

Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD.

Neuro Oncol. 2010 Feb;12(2):116-21. doi: 10.1093/neuonc/nop020. Epub 2009 Dec 14. Erratum in: Neuro Oncol. 2010 Jun;12(6):617.

PMID:
20150378
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.

Salvati M, Pichierri A, Piccirilli M, Floriana Brunetto GM, D'Elia A, Artizzu S, Santoro F, Arcella A, Giangaspero F, Frati A, Simione L, Santoro A.

J Neurosurg. 2012 Aug;117(2):204-11. doi: 10.3171/2012.4.JNS101702. Epub 2012 Jun 1.

PMID:
22655594
[PubMed - indexed for MEDLINE]
12.

O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.

Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T.

Int J Clin Oncol. 2010 Aug;15(4):352-8. doi: 10.1007/s10147-010-0065-6. Epub 2010 Mar 16.

PMID:
20232102
[PubMed - indexed for MEDLINE]
13.

Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.

Lötsch D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, Webersinke G, Pichler J, Berger W, Spiegl-Kreinecker S.

Neuro Oncol. 2013 Apr;15(4):423-32. doi: 10.1093/neuonc/nos329. Epub 2013 Feb 7.

PMID:
23393205
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.

Lee JY, Park CK, Park SH, Wang KC, Cho BK, Kim SK.

Childs Nerv Syst. 2011 Nov;27(11):1877-83. doi: 10.1007/s00381-011-1525-7. Epub 2011 Jul 26.

PMID:
21789683
[PubMed - indexed for MEDLINE]
15.

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.

Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schackert G, Krex D.

J Neurooncol. 2012 Dec;110(3):325-33. doi: 10.1007/s11060-012-0977-2. Epub 2012 Sep 27. Erratum in: J Neurooncol. 2013 Jan;111(1):95. Schrok, E [corrected to Schrock, E].

PMID:
23015095
[PubMed - indexed for MEDLINE]
16.

Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.

Balańa C, Carrato C, Ramírez JL, Cardona AF, Berdiel M, Sánchez JJ, Tarón M, Hostalot C, Musulen E, Ariza A, Rosell R.

Clin Transl Oncol. 2011 Sep;13(9):677-85. doi: 10.1007/s12094-011-0714-x.

PMID:
21865140
[PubMed - indexed for MEDLINE]
17.

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.

Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.

Pediatr Blood Cancer. 2007 Apr;48(4):403-7.

PMID:
16609952
[PubMed - indexed for MEDLINE]
18.

Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.

Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y, Jiang T.

Med Oncol. 2012 Jun;29(2):1292-6. doi: 10.1007/s12032-011-9901-4. Epub 2011 Mar 11.

PMID:
21394635
[PubMed - indexed for MEDLINE]
19.

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY.

J Clin Oncol. 2009 Sep 1;27(25):4150-4. doi: 10.1200/JCO.2009.21.9832. Epub 2009 Jul 27.

PMID:
19636000
[PubMed - indexed for MEDLINE]
20.

A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature.

Zinn PO, Sathyan P, Mahajan B, Bruyere J, Hegi M, Majumder S, Colen RR.

PLoS One. 2012;7(8):e41522. doi: 10.1371/journal.pone.0041522. Epub 2012 Aug 3.

PMID:
22870228
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk